| Globe & Mail (Toronto, Canada) 2003 Leonard Zehr |
| Title | Subject | Authors |
|---|
| Angiotech kills plan for options.(Angiotech Pharmaceuticals Inc., stock option plan) | News, opinion and commentary | Leonard Zehr, Sinclair Stewart |
| Apotex wins legal fight over drug. | News, opinion and commentary | Leonard Zehr |
| Biotech sector consolidation picks up steam.(Inflazyme Pharmaceuticals Ltd. will acquire GlycoDesign Inc. ) | News, opinion and commentary | Leonard Zehr |
| Biotech star seeks the limelight.(biotechnology industry ) | News, opinion and commentary | Leonard Zehr |
| Biovail beats investor anxiety.(Biovail Corp., stock price) | News, opinion and commentary | Leonard Zehr |
| Biovail CEO got top executive pay package.(Biovail Corp., chief executive Eugene Melnyk) | News, opinion and commentary | Leonard Zehr |
| Biovail reduces quarterly guidance. | News, opinion and commentary | Leonard Zehr |
| Biovail won't expense options yet, CEO says.(chief executive) | News, opinion and commentary | Leonard Zehr |
| Bristol-Myers restates results as it erases $2.5-billion in sales.(Bristol-Myers Squibb Co.) | News, opinion and commentary | Leonard Zehr |
| Canadian pharmacy opening U.S. drug centres.(growing trend toward mail order drug firms) | News, opinion and commentary | Leonard Zehr |
| Drug maker Patheon blazes trail.(reports $418 mn in total revenues last year ) | News, opinion and commentary | Leonard Zehr |
| Generic U.S. heartburn drugs may entice Canadian buyers south. | News, opinion and commentary | Leonard Zehr |
| Hemosol CEO takes sick leave at critical time for drug firm.(Hemosol Inc., chief executive) | News, opinion and commentary | Leonard Zehr |
| Hemosol revisits blood substitute.(further clinical testing of blood substitute product) | News, opinion and commentary | Leonard Zehr |
| Lapointe leads ConjuChem comeback.(director of ConjuChem Inc., Jacques Lapointe) | News, opinion and commentary | Leonard Zehr |
| Net pharmacies cheer new U.S. import bill.(Online pharmacies in Canada back new legislation) | News, opinion and commentary | Leonard Zehr |
| No-show U.S. patients hurt TLC.(clinic patients cancel appointments due to SARS fears ) | News, opinion and commentary | Leonard Zehr |
| PanGeo gets court protection. | News, opinion and commentary | Leonard Zehr |
| Pangeo sets deadline for bids on product sales. | News, opinion and commentary | Leonard Zehr |
| Pharmaceutical firm stakes its future on early decision.(new detection device for diagnosing congestive heart failure) | News, opinion and commentary | Leonard Zehr |
| Que. tech firm hits new high.(TSO3 Inc., share value; marketing of medical sterilization device in the U.S.) | News, opinion and commentary | Leonard Zehr |
| U.S. drug boycott threat called 'ridiculous'.(Canadian online pharmacies) | News, opinion and commentary | Leonard Zehr |
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
